Trial reportCancer2012
Treatment outcome in older patients with childhood acute myeloid leukemia.
Trial report in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Differential efficacy of empirical antibiotic therapy for febrile neutropenia in adolescent/young adult (AYA) and child patients.International journal of hematology · 2018Trial
- Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004.Haematologica · 2016Trial
- Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.International journal of hematology · 2015Trial
- Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols.Blood advances · 2026Article
- Preemptive hematopoietic stem cell transplantation inHaematologica · 2026Article
- Article
- Acute kidney injury and childhood acute myeloid leukemia.Pediatric nephrology (Berlin, Germany) · 2022Article
- A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia.Molecular and clinical oncology · 2022Article
- Increased survival disparities among children and adolescents & young adults with acute myeloid leukemia: A Dutch population-based study.International journal of cancer · 2022Article
- Trends in survival of leukemia among children, adolescents, and young adults: A population-based study in Osaka, Japan.Cancer science · 2021Article
- Article
- Antibacterial prophylaxis in pediatric patients with leukemia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018Review
- Acute myelogenous leukemia in adolescents and young adults.Pediatric blood & cancer · 2018Review
- Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.Leukemia · 2018Article
- Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.International journal of hematology · 2018Article
- Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.BioMed research international · 2015Article
- Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.British journal of haematology · 2015Article
- Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2014Article
- Development of treatment and clinical results in childhood acute myeloid leukemia in Poland.Memo · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundOlder age has historically been an adverse prognostic factor in pediatric acute myeloid leukemia (AML). To the authors' knowledge, the impact of age relative to that of other prognostic factors on the outcome of patients treated in recent trials is unknown.
methodsClinical outcome and causes of treatment failure of 351 patients enrolled on 3 consecutive protocols for childhood AML between 1991 and 2008 were analyzed according to age and protocol.
resultsThe more recent protocol (AML02) produced improved outcomes for patients aged 10 years to 21 years compared with 2 earlier studies (AML91 and AML97), with 3-year rates of event-free survival (EFS), overall survival (OS), and cumulative incidence of refractory leukemia or recurrence (CIR) for this group being similar to those of patients aged birth to 9 years: EFS: 58.3% ± 5.4% versus 66.6% ± 4.9% (P = .20); OS: 68.9% ± 5.1% versus 75.1% ± 4.5% (P = .36); and CIR: 21.9% ± 4.4% versus 25.3% ± 4.2% (P = .59). The EFS and OS estimates for patients aged 10 to 15 years overlapped those for patients aged 16 to 21 years. However, the cumulative incidence of toxic death was significantly higher for patients aged 10 to 21 years compared with younger patients (13.2% ± 3.6% vs 4.5% ± 2.0%; P = .028).
conclusionsThe survival rate for older children with AML has improved on the results of a recent trial and is now similar to that of younger patients. However, deaths from toxicity remain a significant problem for patients in the older age group. Future trials should focus on improving supportive care while striving to develop more effective antileukemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.